II (UPII), GATA3, and p40 are highly sensitive markers for the differential diagnosis of invasive urothelial carcinoma.
Pancytokeratin, LCA, CK7, CK20, and uroplakin
GO network analysis classified 13 genes, i.e., catalytic subunit of the oligosaccharyltransferase complex, keratocan, glutamate metabotropic receptor 8 (GRM8), NADH: ubiquinone oxidoreductase subunit B9, dopamine receptor D5 (DRD5), platelet derived growth factor receptor beta (PDGFRB), MACRO domain containing 1, nuclear receptor corepressor 1 (NCOR1), follicle stimulating hormone receptor (FSHR), N-acylsphingosine amidohydrolase 1 (ASAH1), MTSS1, I-BAR domain containing (MTSS1), glutamyl aminopeptidase (ENPEP), and uroplakin
3A, encompassing 118 nsSNPs, into 5 GO terms (p<0.05) that were associated with kidney development and metabolic processes.
Morphologic alterations, mast cell activity, uroplakin
distribution, GAG layer and tight junctions were evaluated by histological techniques, oxidative stress markers; malondialdehyde (MDA) and glutathione (GSH) were analysed by biochemical methods.
Low numbers of cases and no differential diagnostic value regarding the discrimination of urachal adenocarcinomas from primary bladder and colorectal adenocarcinomas were detected for [alpha]-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9), cluster of differentiation 10 (CD10), CK19, Das-1, E48, E-Cadherin, gross cystic disease fluid protein 15 (GCDFP15), mucin 1 (epithelial membrane antigen) (MUC1 (EMA)), mucin 6 (MUC6), Thrombmodulin, thyroid transcription factor 1 (TTF1), Uroplakin
III, Villin, and Vimentin [27, 48, 60, 86, 100, 106, 125, 126, 172, 198, 215, 217, 245, 292, 330].
On pathological examination, adenocarcinoma and SCC were detected (Figure 2(b)); on immunohistochemistry, sections of the tumor were positive for the SCC markers CD56, chromogranin A, and synaptophysin and were negative for the urothelial carcinoma markers GATA-3, p63, uroplakin
, thrombomodulin, and 34[beta]E12.
Immunohistochemistry (IHC) of the urothelial carcinoma showed cytoplasmic and membrane positivity for Uroplakin
II (Figure 5).
The malignant cells are immunoreactive for uroplakin
and MOC-31 while negative for calretinin (not shown).
Immunohistochemical study revealed total loss of INI-1 expression (figure 4); positive staining of vimentin (figure 5), panCK (figure 6), CK19 (figure 7), and PAX8; and negative staining of CK7, CK20, p63, uroplakin
, CD 10, and 34BE12 (figure 8).
Immunohistochemical (IHC) stains showed cytokeratin 7 positive, cytokeratin 20 positive (Figure 5), Caudal Type Homeobox 2 (CDX2) positive (Figure 6), GATA3 negative in neoplastic cells (Figure 7), and Uroplakin
negative in neoplastic cells (Figure 8).
Concmonoclonal IHC antibodies Uroplakin
II (Clone BC21)
The immunophenotype of TCC of the ovary is similar to that of other surface carcinomas of the ovary, but differs from that of TCC of the bladder.2 In addition, ovarian TCCs are negative for CK20, Thrombomodulin (TM) and uroplakin
III, which are the antigens that are usually (CK20) or sometimes (TM and uroplakin
III) detected in bladder TCCs.